Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166816 | 0.84 | PDE10A (0.42) | PDE10AHPGDSPIK3CAMTORATR | |
| SCHEMBL3946680 | 0.74 | PDE10A (0.52) | PDE10AHPGDSLMNASMN1; SMN2 | |
| SCHEMBL4163018 | 0.72 | GPR119 (0.37) | PDE10AHPGDSPIK3CAMTORCYP11B2 | |
| SCHEMBL4171535 | 0.72 | PDE10A (0.50) | PDE10AHPGDSPIK3CAMTORATR | |
| SCHEMBL27697973 | 0.71 | ADRB2 (0.43) | — | |
| SCHEMBL17838760 | 0.71 | KDM4E (0.40) | SMN1; SMN2 | |
| SCHEMBL4195075 | 0.66 | PDE10A (0.54) | PDE10AHPGDSPIK3CAMTORATR | |
| SCHEMBL20361318 | 0.65 | TRPV1 (0.44) | HPGDSTRPV1 | |
| SCHEMBL20361250 | 0.65 | PANK3 (0.44) | PDE10AHPGDSPIK3CAMTORATR | |
| SCHEMBL22587570 | 0.65 | GRIN2D (0.46) | PDE10APIK3CAMTORTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE4A, PDE4B | PDE10A 8/4885HPGDS 2513/4885PIK3CA 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.